|
|
|
Volumn 37, Issue 4, 2007, Pages 941-968
|
|
Vioxx's history and the need for better procedures and better testing.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOOXYGENASE 2 INHIBITOR;
LACTONE;
SULFONE;
ARTHRITIS;
ARTICLE;
CARDIOVASCULAR DISEASE;
CHEMICALLY INDUCED DISORDER;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG LABELING;
DRUG SCREENING;
DRUG SURVEILLANCE PROGRAM;
FOOD AND DRUG ADMINISTRATION;
GOVERNMENT REGULATION;
HISTORY;
HUMAN;
LEGAL ASPECT;
POSTMARKETING SURVEILLANCE;
SAFETY;
UNITED STATES;
ADVERSE DRUG REACTION REPORTING SYSTEMS;
ARTHRITIS;
CARDIOVASCULAR DISEASES;
CLINICAL TRIALS AS TOPIC;
CONSUMER PRODUCT SAFETY;
CYCLOOXYGENASE 2 INHIBITORS;
DRUG APPROVAL;
DRUG EVALUATION, PRECLINICAL;
DRUG INDUSTRY;
DRUG LABELING;
GOVERNMENT REGULATION;
HISTORY, 20TH CENTURY;
HISTORY, 21ST CENTURY;
HUMANS;
LACTONES;
PRODUCT SURVEILLANCE, POSTMARKETING;
SULFONES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 41949139756
PISSN: 05865964
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (18)
|
|
References (0)
|
